Clinical Trial Update: Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries [Phase 3]

View source ↗

Summary

Amgen's Fourier open-label extension study in adults with clinically evident cardiovascular disease and dyslipidemia was terminated, with results posted in Janu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Dyslipidemia

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2023-01-11